Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.

Trump’s White House juggled a devastating American Airline flight-Black Hawk helicopter crash, a Chinese AI threat and looming tariffs just this week alone, making for a busy start to his four-year ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Shares of ResMed (NYSE:RMD) fell 6% today, despite the company reporting second-quarter earnings that surpassed analyst ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

The stock market showed resilience after Monday's DeepSeek-spurred sell-off in AI hardware stocks. Apple, Tesla, Microsoft led big earnings.

BMO Capital Markets increased its price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares, moving the ...

Labcorp Holdings Inc. LH, or Labcorp, is slated to report its fourth-quarter 2024 results on Feb. 6 before the opening bell.

DeepSeek Launch, Intel’s Price Cuts The unveiling of China’s new resource-light AI model, DeepSeek, roiled the U.S. big ...

Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against ...

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...